Loading organizations...
§ Public · La Jolla, CA, USA
Clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses.
Based in La Jolla, California, CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies targeting acute and chronic inflammatory and immunologic illnesses. The publicly traded enterprise operates on the Nasdaq under the ticker symbol CALC and has secured capital through funding rounds, including a $21 million Series D financing. The firm's institutional backers include venture capital investors such as Quark Venture. The company's clinical pipeline focuses on severe medical conditions, with recent research abstracts accepted for presentation at the American Pancreatic Association and Emergencies in Medicine meetings. Currently led by Chief Executive Officer Rachel Leheny, the organization continues to advance its therapeutic candidates. CalciMedica was founded in 2007 by scientists Kenneth Stauderman and Gonul Velicelebi, originating from research conducted at Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research.
CalciMedica has raised $54.0M across 5 funding rounds.
CalciMedica has raised $54.0M in total across 5 funding rounds.
CalciMedica has raised $54.0M across 5 funding rounds. Most recently, it raised $21.0M Series D in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 11, 2021 | $21M Series D | GF Securities, Karimah ES Sabar | Sanderling Ventures, Valence Life Sciences | Announced |
| May 25, 2020 | $15M Series C | Eric Roberts | Bering Capital, Mesa Verde Venture Partners, Sanderling Ventures | Announced |
| Dec 1, 2009 | $12M Series C | — | SR ONE | Announced |
| Jan 1, 2009 | $4M Series C | — | SR ONE | Announced |
| Jul 1, 2007 | $2M Series A | SR ONE | — | Announced |
CalciMedica is a clinical-stage biopharmaceutical company specializing in the development of novel therapies based on CRAC (calcium release-activated calcium) channel inhibition. Its lead product, Auxora™, is an intravenous small molecule designed to treat acute inflammatory and immunologic diseases such as acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP), conditions with high unmet medical needs and no currently approved disease-modifying treatments. CalciMedica aims to modulate the immune response and protect tissue cells from injury, targeting life-threatening acute illnesses primarily in intensive care settings[1][3].
Founded in 2007 by scientists including Dr. Kenneth A. Stauderman, who has over 30 years of expertise in intracellular calcium mechanisms, CalciMedica emerged from research focused on CRAC channels and their role in inflammatory diseases. The company has advanced Auxora™ through multiple Phase 2 clinical trials, demonstrating consistent positive results and a favorable safety profile. Early traction includes recognition as a leader in CRAC channel inhibition therapies and ongoing clinical development in acute inflammatory conditions[3][6].
CalciMedica is positioned at the intersection of immunology, critical care medicine, and precision biopharmaceutical innovation. It rides the trend of targeting immune modulation in acute inflammatory diseases, a field gaining importance due to the high morbidity and mortality associated with conditions like AKI and AP. The timing is critical as there are currently no approved disease-modifying treatments for these conditions, and the healthcare burden is substantial, with over 1 million hospital patient days and costs exceeding $3 billion annually in the US alone for AP[1]. By developing therapies that can improve outcomes in intensive care units, CalciMedica contributes to advancing acute care therapeutics and potentially reshaping standards of care.
CalciMedica’s near-term trajectory involves advancing Auxora™ through further clinical trials to potentially secure regulatory approval and broaden its application in acute inflammatory diseases. Future trends shaping its journey include increasing recognition of immune modulation in critical illness and the growing need for targeted therapies in acute care settings. As the company progresses, its influence may expand by establishing CRAC channel inhibition as a validated therapeutic approach, potentially opening new avenues for treating other inflammatory and immunologic conditions. This positions CalciMedica as a pioneering force in a niche yet impactful segment of biopharmaceutical innovation[3][1].
CalciMedica has raised $54.0M in total across 5 funding rounds.
CalciMedica's investors include GF Securities, Karimah Es Sabar, Sanderling Ventures, Valence Life Sciences, Eric Roberts, Bering Capital, Mesa Verde Venture Partners, SR One.